Mehta-Shah, N., Moskowitz, A. J., Lunning, M. A., Lynch, P., Scheuerman, M., Minnal, V., … Horwitz, S. M. (2017). A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B-and T-Cell Lymphomas. In BLOOD (Vol. 130).

Mehta-Shah, Neha, Alison J. Moskowitz, Matthew A. Lunning, Peggy Lynch, Mark Scheuerman, Veenna Minnal, Natasha Galasso, et al. “A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B-and T-Cell Lymphomas.” In BLOOD, Vol. 130, 2017.

Mehta-Shah N, Moskowitz AJ, Lunning MA, Lynch P, Scheuerman M, Minnal V, et al. A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B-and T-Cell Lymphomas. In: BLOOD. 2017.

Mehta-Shah, Neha, et al. “A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B-and T-Cell Lymphomas.” BLOOD, vol. 130, 2017.

Mehta-Shah N, Moskowitz AJ, Lunning MA, Lynch P, Scheuerman M, Minnal V, Galasso N, Kumar A, Gerecitano J, Zelenetz AD, Hamlin PA, Noy A, Matasar MJ, Palomba ML, Younes A, Schaffer W, Grewal R, Rademaker J, Sauter CS, Dahi PB, Myskowski P, Kheterpal M, Dogan A, Pulitzer M, Lubin L, Tang L, Ganesan N, Ni A, Horwitz SM. A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B-and T-Cell Lymphomas. BLOOD. 2017.